🇺🇸 FDA
Pipeline program

MK-1022, -, -, -

MK-1022-011

Phase 2 small_molecule active

Quick answer

MK-1022, -, -, - for Colorectal Carcinoma, Biliary Tract Carcinoma, Hepatocellular Carcinoma​ is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Colorectal Carcinoma, Biliary Tract Carcinoma, Hepatocellular Carcinoma​
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials